US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

ABIOMED, Inc. - Common Stock (NQ:ABMD)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABIOMED, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
From Abiomed, Inc.
Via Business Wire
News headline image
Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
News headline image
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
From Abiomed, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 ↗
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE: 
Via Benzinga
News headline image
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
From Abiomed
Via Business Wire
News headline image
Abiomed to Present at Upcoming Investor Conferences
From Abiomed, Inc.
Via Business Wire
News headline image
Avoid the Dogecoin Crash by Buying These 2 Growth Stocks Instead ↗
Dogecoin may be breaking its all-time highs every other day, but there's nothing averting a catastrophic fall. 
Via The Motley Fool
Topics Retirement
News headline image
Abiomed to Shareholders: Patience Please, Growth Is On The Way. ↗
Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming. 
Via The Motley Fool
Topics Earnings
News headline image
Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript ↗
ABMD earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
From Abiomed, Inc.
Via Business Wire
News headline image
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella
From Abiomed, Inc.
Via Business Wire
News headline image
Dr. Paula A. Johnson Joins Abiomed Board of Directors
From Abiomed
Via Business Wire
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
News headline image
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
From Abiomed, Inc.
Via Business Wire
News headline image
Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >